Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes Therapy
Glycemic and lipidemic effect of monopril and losartan investigated
September 27th, 2004
Researchers report the results of studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats. "The effects of the angiotensin-converting enzyme (ACE) inhibitor monopril and the angiotensin II receptor blocker losartan on serum glucose, protein levels and some serum lipid components were compared in normal and diabetic rats receiving oral antidiabetic drugs repaglinide or gliclazide. The two antihypertensive agents, when administered concurrently with oral hypoglycemic agents repaglinide or gliclazide in normal and diabetic rats exerted a significant hypoglycemic effect. Serum protein levels were mainly unaffected by the two...
Source: Obesity & Diabetes Week (2004-09-27)
|
